New combo targets hard-to-treat lung cancer mutation in early trial

NCT ID NCT06249282

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Apr 04, 2026 · Last updated May 12, 2026 · Updated 5 times

Summary

This early-stage trial tests whether combining two drugs, carfilzomib and sotorasib, is safe and effective for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. About 15 adults who have already tried a KRAS-targeting drug will receive the combination. The main goal is to find the best dose and identify any serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
City of Hope at Irvine Lennar
RECRUITING

Irvine, California, 92618, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

ADVANCED LUNG NON-SMALL CELL CARCINOMA METASTATIC LUNG NON-SMALL CELL CARCINOMA STAGE III LUNG CANCER AJCC V8 STAGE III LUNG CANCER AJCC V8 STAGE IV LUNG CANCER AJCC V8 STAGE IV LUNG CANCER AJCC V8